Committed to improving women’s health and quality of life
Potential breakthrough therapy for uterine fibroids and endometriosis.
Protected by two US patents (10,251,836 and 11,116,718).Clinical efficacy testing starts with Phase IIb.
Optimal use of the most promising drug: ultra-low doses of a specific Selective Progesterone Receptor Modulator (SPRM) are delivered by a novel route, directly to affected tissues:
Greater Efficacy: High local drug concentrations result in strong therapeutic action at a small fraction of oral dose – superior to other therapies.
Limited Side Effects: Unlike other hormonal therapies (e.g., Lupron Depot®), Premring will NOT be associated with severe menopausal symptoms, such as hot flashes and bone loss.
Safe Long-Term Therapy: Improved safety permits long-term treatment (not an option for other hormonal medications), greatly reducing the need for hospitalizations and radical surgeries.